Kynurenine suppresses osteoblastic cell energetics in vitro and osteoblast numbers in vivo

Jessica L. Pierce, Rachel L. Roberts, Kanglun Yu, Riley K. Kendall, Helen Kaiser, Colleen Davis, Maribeth H. Johnson, William D. Hill, Carlos M. Isales, Wendy B. Bollag, Mark W. Hamrick, Meghan E. McGee-Lawrence

Research output: Contribution to journalArticle

Abstract

Aging is a progressive process associated with declining tissue function over time. Kynurenine, an oxidized metabolite of the essential amino acid tryptophan that increases in abundance with age, drives cellular processes of aging and dysfunction in many tissues, and recent work has focused on understanding the pathways involved in the harmful effects of kynurenine on bone. In this study, we sought to investigate the effects of controlled kynurenine administration on osteoblast bioenergetics, in vivo osteoblast abundance, and marrow fat accumulation. Additionally, as an extension of earlier studies with dietary administration of kynurenine, we investigated the effects of kynurenine on Hdac3 and NCoR1 expression and enzymatic deacetylase activity as potential mechanistic contributors to the effects of kynurenine on osteoblasts. Kynurenine administration suppressed cellular metabolism in osteoblasts at least in part through impaired mitochondrial respiration, and suppressed osteoblastic numbers in vivo with no concurrent effects on marrow adiposity. Deleterious effects of kynurenine treatment on osteoblasts were more pronounced in female models as compared to males. However, kynurenine treatment did not inhibit Hdac3's enzymatic deacetylase activity nor its repression of downstream glucocorticoid signaling. As such, future work will be necessary to determine the mechanisms by which increased kynurenine contributes to aging bone bioenergetics. The current study provides novel further support for the idea that kynurenine contributes to impaired osteoblastic function, and suggests that impaired matrix production by kynurenine-affected osteoblasts is attributed in part to impaired osteoblastic bioenergetics. As circulating kynurenine levels in increase with age, and human bone density inversely correlates with the serum kynurenine to tryptophan ratio, these mechanisms may have important relevance in the etiology and pathogenesis of osteoporosis in humans.

Original languageEnglish (US)
Article number110818
JournalExperimental Gerontology
Volume130
DOIs
StatePublished - Feb 2020

Fingerprint

Kynurenine
Osteoblasts
Energy Metabolism
Bone
Aging of materials
In Vitro Techniques
Tryptophan
Bone Marrow
Tissue
Bone and Bones
Essential Amino Acids
Cell Aging
Adiposity
Metabolites
Metabolism
Bone Density

Keywords

  • Aging
  • Bone
  • Energy metabolism
  • Histone deacetylase 3
  • Kynurenine
  • Marrow fat
  • Osteoblast

ASJC Scopus subject areas

  • Biochemistry
  • Aging
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Cell Biology

Cite this

Pierce, J. L., Roberts, R. L., Yu, K., Kendall, R. K., Kaiser, H., Davis, C., ... McGee-Lawrence, M. E. (2020). Kynurenine suppresses osteoblastic cell energetics in vitro and osteoblast numbers in vivo. Experimental Gerontology, 130, [110818]. https://doi.org/10.1016/j.exger.2019.110818

Kynurenine suppresses osteoblastic cell energetics in vitro and osteoblast numbers in vivo. / Pierce, Jessica L.; Roberts, Rachel L.; Yu, Kanglun; Kendall, Riley K.; Kaiser, Helen; Davis, Colleen; Johnson, Maribeth H.; Hill, William D.; Isales, Carlos M.; Bollag, Wendy B.; Hamrick, Mark W.; McGee-Lawrence, Meghan E.

In: Experimental Gerontology, Vol. 130, 110818, 02.2020.

Research output: Contribution to journalArticle

Pierce, Jessica L. ; Roberts, Rachel L. ; Yu, Kanglun ; Kendall, Riley K. ; Kaiser, Helen ; Davis, Colleen ; Johnson, Maribeth H. ; Hill, William D. ; Isales, Carlos M. ; Bollag, Wendy B. ; Hamrick, Mark W. ; McGee-Lawrence, Meghan E. / Kynurenine suppresses osteoblastic cell energetics in vitro and osteoblast numbers in vivo. In: Experimental Gerontology. 2020 ; Vol. 130.
@article{7a0c4440b74b4c4d8fa1ee8accc7da6a,
title = "Kynurenine suppresses osteoblastic cell energetics in vitro and osteoblast numbers in vivo",
abstract = "Aging is a progressive process associated with declining tissue function over time. Kynurenine, an oxidized metabolite of the essential amino acid tryptophan that increases in abundance with age, drives cellular processes of aging and dysfunction in many tissues, and recent work has focused on understanding the pathways involved in the harmful effects of kynurenine on bone. In this study, we sought to investigate the effects of controlled kynurenine administration on osteoblast bioenergetics, in vivo osteoblast abundance, and marrow fat accumulation. Additionally, as an extension of earlier studies with dietary administration of kynurenine, we investigated the effects of kynurenine on Hdac3 and NCoR1 expression and enzymatic deacetylase activity as potential mechanistic contributors to the effects of kynurenine on osteoblasts. Kynurenine administration suppressed cellular metabolism in osteoblasts at least in part through impaired mitochondrial respiration, and suppressed osteoblastic numbers in vivo with no concurrent effects on marrow adiposity. Deleterious effects of kynurenine treatment on osteoblasts were more pronounced in female models as compared to males. However, kynurenine treatment did not inhibit Hdac3's enzymatic deacetylase activity nor its repression of downstream glucocorticoid signaling. As such, future work will be necessary to determine the mechanisms by which increased kynurenine contributes to aging bone bioenergetics. The current study provides novel further support for the idea that kynurenine contributes to impaired osteoblastic function, and suggests that impaired matrix production by kynurenine-affected osteoblasts is attributed in part to impaired osteoblastic bioenergetics. As circulating kynurenine levels in increase with age, and human bone density inversely correlates with the serum kynurenine to tryptophan ratio, these mechanisms may have important relevance in the etiology and pathogenesis of osteoporosis in humans.",
keywords = "Aging, Bone, Energy metabolism, Histone deacetylase 3, Kynurenine, Marrow fat, Osteoblast",
author = "Pierce, {Jessica L.} and Roberts, {Rachel L.} and Kanglun Yu and Kendall, {Riley K.} and Helen Kaiser and Colleen Davis and Johnson, {Maribeth H.} and Hill, {William D.} and Isales, {Carlos M.} and Bollag, {Wendy B.} and Hamrick, {Mark W.} and McGee-Lawrence, {Meghan E.}",
year = "2020",
month = "2",
doi = "10.1016/j.exger.2019.110818",
language = "English (US)",
volume = "130",
journal = "Experimental Gerontology",
issn = "0531-5565",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Kynurenine suppresses osteoblastic cell energetics in vitro and osteoblast numbers in vivo

AU - Pierce, Jessica L.

AU - Roberts, Rachel L.

AU - Yu, Kanglun

AU - Kendall, Riley K.

AU - Kaiser, Helen

AU - Davis, Colleen

AU - Johnson, Maribeth H.

AU - Hill, William D.

AU - Isales, Carlos M.

AU - Bollag, Wendy B.

AU - Hamrick, Mark W.

AU - McGee-Lawrence, Meghan E.

PY - 2020/2

Y1 - 2020/2

N2 - Aging is a progressive process associated with declining tissue function over time. Kynurenine, an oxidized metabolite of the essential amino acid tryptophan that increases in abundance with age, drives cellular processes of aging and dysfunction in many tissues, and recent work has focused on understanding the pathways involved in the harmful effects of kynurenine on bone. In this study, we sought to investigate the effects of controlled kynurenine administration on osteoblast bioenergetics, in vivo osteoblast abundance, and marrow fat accumulation. Additionally, as an extension of earlier studies with dietary administration of kynurenine, we investigated the effects of kynurenine on Hdac3 and NCoR1 expression and enzymatic deacetylase activity as potential mechanistic contributors to the effects of kynurenine on osteoblasts. Kynurenine administration suppressed cellular metabolism in osteoblasts at least in part through impaired mitochondrial respiration, and suppressed osteoblastic numbers in vivo with no concurrent effects on marrow adiposity. Deleterious effects of kynurenine treatment on osteoblasts were more pronounced in female models as compared to males. However, kynurenine treatment did not inhibit Hdac3's enzymatic deacetylase activity nor its repression of downstream glucocorticoid signaling. As such, future work will be necessary to determine the mechanisms by which increased kynurenine contributes to aging bone bioenergetics. The current study provides novel further support for the idea that kynurenine contributes to impaired osteoblastic function, and suggests that impaired matrix production by kynurenine-affected osteoblasts is attributed in part to impaired osteoblastic bioenergetics. As circulating kynurenine levels in increase with age, and human bone density inversely correlates with the serum kynurenine to tryptophan ratio, these mechanisms may have important relevance in the etiology and pathogenesis of osteoporosis in humans.

AB - Aging is a progressive process associated with declining tissue function over time. Kynurenine, an oxidized metabolite of the essential amino acid tryptophan that increases in abundance with age, drives cellular processes of aging and dysfunction in many tissues, and recent work has focused on understanding the pathways involved in the harmful effects of kynurenine on bone. In this study, we sought to investigate the effects of controlled kynurenine administration on osteoblast bioenergetics, in vivo osteoblast abundance, and marrow fat accumulation. Additionally, as an extension of earlier studies with dietary administration of kynurenine, we investigated the effects of kynurenine on Hdac3 and NCoR1 expression and enzymatic deacetylase activity as potential mechanistic contributors to the effects of kynurenine on osteoblasts. Kynurenine administration suppressed cellular metabolism in osteoblasts at least in part through impaired mitochondrial respiration, and suppressed osteoblastic numbers in vivo with no concurrent effects on marrow adiposity. Deleterious effects of kynurenine treatment on osteoblasts were more pronounced in female models as compared to males. However, kynurenine treatment did not inhibit Hdac3's enzymatic deacetylase activity nor its repression of downstream glucocorticoid signaling. As such, future work will be necessary to determine the mechanisms by which increased kynurenine contributes to aging bone bioenergetics. The current study provides novel further support for the idea that kynurenine contributes to impaired osteoblastic function, and suggests that impaired matrix production by kynurenine-affected osteoblasts is attributed in part to impaired osteoblastic bioenergetics. As circulating kynurenine levels in increase with age, and human bone density inversely correlates with the serum kynurenine to tryptophan ratio, these mechanisms may have important relevance in the etiology and pathogenesis of osteoporosis in humans.

KW - Aging

KW - Bone

KW - Energy metabolism

KW - Histone deacetylase 3

KW - Kynurenine

KW - Marrow fat

KW - Osteoblast

UR - http://www.scopus.com/inward/record.url?scp=85076669998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076669998&partnerID=8YFLogxK

U2 - 10.1016/j.exger.2019.110818

DO - 10.1016/j.exger.2019.110818

M3 - Article

C2 - 31862422

AN - SCOPUS:85076669998

VL - 130

JO - Experimental Gerontology

JF - Experimental Gerontology

SN - 0531-5565

M1 - 110818

ER -